Bio-Rad Laboratories Inc
Latest Bio-Rad Laboratories Inc News and Updates
Myriad Genetics Expected to Report Flat Revenue Growth in Fiscal 2018
Myriad Genetics (MYGN) expects to report revenues in the range of $750 million–$770 million in fiscal 2018 (ended June 30, 2018).
Thermo Fisher Expands Its Partnership with Genome Diagnostics
In December 2017, Thermo Fisher Scientific (TMO) expanded its partnership with Genome Diagnostics (or GenDx), a Netherlands-based firm offering molecular diagnostics solutions.
What Bio-Rad Laboratories Expects from Life Science
In 1Q17, Bio-Rad Laboratories’ (BIO) Life Science segment reported revenues of ~$174.3 million, which represents a YoY rise of ~5.1%.
Inside Bio-Rad Laboratories’ Robust Revenue Growth Projection for 2017
On March 13, 2017, Bio-Rad Laboratories (BIO) provided a long-term, currency-neutral revenue growth target of around 3%–5%.
